全球基因测序和芯片技术领导者Illumina(ILMN)今日股价盘中大涨5.11%,投资者对该公司的发展前景持续看好。
从技术创新方面来看,Illumina宣布与多家医药企业合作,利用新推出的蛋白质组学解决方案Illumina Protein Prep启动一项大规模试点项目。此举标志着Illumina在多组学领域的技术日益成熟,有望帮助制药企业发现新的药物靶点,提升Illumina在生命科学领域的影响力。
除此之外,Illumina公布了2024年初步财报数据。公司2024年全年收入同比下降2%至43.3亿美元,但第四季度收入1.1亿美元,同比微增1%。此外,现金流和利润率也保持在较好水平。可见尽管受到一定不利影响,但公司核心业务仍保持稳健增长。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.